‘We now have the clinical data package to support global submissions for retatrutide as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea.’ Key takeaways:Retatrutide met primary endpoints in the TRIUMPH-2 and TRIUMPH-3 trials, delivering substantial weight loss at 80 weeks. The clinical data package will support global submissions for the drug as a potential treatment for obesity, knee osteoarthritis pain, and obstructive sleep apnea. Eli Lilly and Company recently shared positive topline results from two pivotal phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. Detailed results from TRIUMPH-2 and TRIUMPH-3 will be presented at future medical meetings and published in peer-reviewed journals.